DR. JEFFREY M. HARDACRE (Cleveland, Ohio): The Indiana group under the lead of our program chair, Dr. Schmidt, continues to be a national leader in the study of pancreatic cystic neoplasms. Their previous work has looked at blood as well as cyst fluid markers to differentiate mucin producing from non-mucin producing cysts as well as to estimate IPMN risk of harboring high grade dysplasia or invasive cancer versus low to moderate grade dysplasia. The ability to more accurately differentiate high risk from low risk IPMNs would add greatly to the currently available consensus guidelines for the management of this increasingly present disease. Identifying a biomarker to pancreatic cyst malignant potential could also aid in the search for a screening test for pancreatic cancer. Currently there is no such screening test available for the general population. For high risk patients, the CAPS study utilizes frequent MR and endoscopic ultrasound evaluation to detect precursor lesions or early cancers, but we are in desperate need of a screening test for the general population to look for early cancers or, even better, to find the precancerous lesions. Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?The American Journal of SurgeryVol. 219Issue 3PreviewIntraductal papillary mucinous neoplasms (IPMN) are precursors of pancreatic cancer. Potential biomarkers of IPMN progression have not been identified in urine. A few urinary biomarkers were reported to be predictive of pancreatic ductal adenocarcinoma (PDAC). Here, we seek to assess their ability to detect high-risk IPMN. Full-Text PDF